Published in Physiol Genomics on October 31, 2006
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron (2008) 3.08
What would you do if you could sequence everything? Nat Biotechnol (2008) 2.89
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging (2008) 1.60
Necroptosis activation in Alzheimer's disease. Nat Neurosci (2017) 1.38
Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging (2008) 1.24
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology (2015) 1.21
Unveiling clusters of RNA transcript pairs associated with markers of Alzheimer's disease progression. PLoS One (2012) 1.18
Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer's disease. Neural Plast (2010) 1.07
Down-weighting overlapping genes improves gene set analysis. BMC Bioinformatics (2012) 1.05
Gene network effects on brain microstructure and intellectual performance identified in 472 twins. J Neurosci (2012) 1.04
PathNet: a tool for pathway analysis using topological information. Source Code Biol Med (2012) 1.01
Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiol Aging (2008) 1.00
Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS One (2012) 1.00
Gene expression reveals overlap between normal aging and Alzheimer's disease genes. Neurobiol Aging (2010) 0.97
Functional genomics of brain aging and Alzheimer's disease: focus on selective neuronal vulnerability. Curr Genomics (2010) 0.97
Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol (2012) 0.94
NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies. PLoS Biol (2016) 0.90
'Neuroinflammation' differs categorically from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and inflammatory diseases compared. Neurogenetics (2014) 0.88
Pathway network inference from gene expression data. BMC Syst Biol (2014) 0.88
Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J Biol Chem (2010) 0.88
Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures. Oxid Med Cell Longev (2013) 0.87
Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer's disease pathophysiology. PLoS One (2013) 0.87
NMNATs, evolutionarily conserved neuronal maintenance factors. Trends Neurosci (2013) 0.87
Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. Transl Psychiatry (2011) 0.86
A searchable cross-platform gene expression database reveals connections between drug treatments and disease. BMC Genomics (2012) 0.86
Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Chem Neuroanat (2011) 0.86
Considerations in the design of clinical trials for cognitive aging. J Gerontol A Biol Sci Med Sci (2012) 0.85
Comparative study on gene set and pathway topology-based enrichment methods. BMC Bioinformatics (2015) 0.85
cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc Natl Acad Sci U S A (2014) 0.85
Identification of unstable network modules reveals disease modules associated with the progression of Alzheimer's disease. PLoS One (2013) 0.85
Proteome-wide discovery of mislocated proteins in cancer. Genome Res (2013) 0.83
Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes. Transl Psychiatry (2011) 0.83
A computational procedure for functional characterization of potential marker genes from molecular data: Alzheimer's as a case study. BMC Med Genomics (2011) 0.82
Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease. J R Soc Interface (2013) 0.82
Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease. Mol Ther Nucleic Acids (2015) 0.82
Transcriptome meta-analysis reveals a central role for sex steroids in the degeneration of hippocampal neurons in Alzheimer's disease. BMC Syst Biol (2013) 0.81
Prefrontal-enriched SLIT1 expression in Old World monkey cortex established during the postnatal development. Cereb Cortex (2010) 0.79
Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole. Mol Psychiatry (2016) 0.78
[Not Available]. Front Neuroinform (2009) 0.78
A rat brain bicistronic gene with an internal ribosome entry site codes for a phencyclidine-binding protein with cytotoxic activity. J Biol Chem (2008) 0.78
Using bioconductor package BiGGR for metabolic flux estimation based on gene expression changes in brain. PLoS One (2015) 0.78
Gene expression profiling and its practice in drug development. Curr Genomics (2007) 0.78
SPIEDw: a searchable platform-independent expression database web tool. BMC Genomics (2013) 0.78
The Na+/H+ exchanger NHE6 modulates endosomal pH to control processing of amyloid precursor protein in a cell culture model of Alzheimer disease. J Biol Chem (2015) 0.78
Co-expression network-based analysis of hippocampal expression data associated with Alzheimer's disease using a novel algorithm. Exp Ther Med (2016) 0.77
A systems approach to drug discovery in Alzheimer's disease. Neurotherapeutics (2015) 0.77
A transcriptional signature of Alzheimer's disease is associated with a metastable subproteome at risk for aggregation. Proc Natl Acad Sci U S A (2016) 0.77
Neuroinflammation and copper in Alzheimer's disease. Int J Alzheimers Dis (2013) 0.77
The Brain Metabolome of Male Rats across the Lifespan. Sci Rep (2016) 0.76
Roar: detecting alternative polyadenylation with standard mRNA sequencing libraries. BMC Bioinformatics (2016) 0.75
Complementarity of medium-throughput in situ RNA hybridization and tissue-specific transcriptomics: case study of Arabidopsis seed development kinetics. Sci Rep (2016) 0.75
SPATIAL: A System-level PAThway Impact AnaLysis approach. Nucleic Acids Res (2016) 0.75
Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons. Sci Rep (2017) 0.75
Integrated analysis of differential gene expression profiles in hippocampi to identify candidate genes involved in Alzheimer's disease. Mol Med Rep (2015) 0.75
Adaptive thresholds to detect differentially expressed genes in microarray data. Bioinformation (2011) 0.75
RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. Transl Psychiatry (2016) 0.75
Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis. Front Aging Neurosci (2017) 0.75
Single-cell and regional gene expression analysis in Alzheimer's disease. Cell Mol Neurobiol (2012) 0.75
Differences of immune disorders between Alzheimer's disease and breast cancer based on transcriptional regulation. PLoS One (2017) 0.75
A default mode of brain function. Proc Natl Acad Sci U S A (2001) 50.73
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 29.13
The glutamate receptor ion channels. Pharmacol Rev (1999) 15.06
Long-term potentiation--a decade of progress? Science (1999) 10.24
Gene regulation and DNA damage in the ageing human brain. Nature (2004) 9.01
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (1984) 6.86
Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet (2000) 6.61
Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev (1999) 6.38
Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem (1998) 6.26
Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A (2004) 5.65
Dynactin. Annu Rev Cell Dev Biol (2004) 5.46
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev (2000) 5.40
Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci (2005) 5.01
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Neural plasticity in the ageing brain. Nat Rev Neurosci (2006) 4.66
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci (2001) 3.56
Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci (2001) 3.35
A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology (1988) 3.28
Targeting of PKA to glutamate receptors through a MAGUK-AKAP complex. Neuron (2000) 3.03
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging (1992) 2.97
Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci (1985) 2.72
The genomic action potential. Neurobiol Learn Mem (2000) 2.68
Rabphilin-3A, a putative target protein for smg p25A/rab3A p25 small GTP-binding protein related to synaptotagmin. Mol Cell Biol (1993) 2.48
Calcineurin. Adv Enzymol Relat Areas Mol Biol (1988) 2.43
Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet (2004) 2.33
Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology (1998) 2.24
Neocortical cell counts in normal human adult aging. Ann Neurol (1987) 2.16
Modified hippocampal long-term potentiation in PKC gamma-mutant mice. Cell (1993) 2.14
Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons. Nature (1994) 2.09
Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet (1989) 2.02
NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. Trends Neurosci (2002) 1.92
Atrophy rates of entorhinal cortex in AD and normal aging. Neurology (2003) 1.88
Postsynaptic protein phosphorylation and LTP. Trends Neurosci (2000) 1.87
MRI of entorhinal cortex in mild Alzheimer's disease. Lancet (1999) 1.86
Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology (1999) 1.78
Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex (1994) 1.73
Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging. Neurology (1992) 1.72
A novel mitogen-activated protein kinase phosphatase. Structure, expression, and regulation. J Biol Chem (1995) 1.64
Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med (1995) 1.64
Functionally distinct isoforms of dynactin are expressed in human neurons. Mol Biol Cell (1996) 1.57
Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. AJNR Am J Neuroradiol (2001) 1.53
Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience (1996) 1.33
The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res (1992) 1.30
Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology (1984) 1.29
The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res (2005) 1.23
Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia (1989) 1.22
Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia (1994) 1.22
Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann N Y Acad Sci (1996) 1.18
Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life (2004) 1.15
Protein kinase C injection into hippocampal pyramidal cells elicits features of long term potentiation. Nature (1987) 1.15
Localization of Rabphilin-3A on the synaptic vesicle. Biochem Biophys Res Commun (1994) 1.11
Molecular mechanisms associated with long-term consolidation of the NMDA signals. Life Sci (2000) 1.05
A-kinase anchor protein 75 increases the rate and magnitude of cAMP signaling to the nucleus. Curr Biol (1997) 1.01
Regional expression of RGS4 mRNA in human brain. Eur J Neurosci (2004) 1.01
Convergence of PKC-dependent kinase signal cascades on NMDA receptors. Curr Drug Targets (2001) 1.00
Tau protein in normal and Alzheimer's disease brain: an update. J Alzheimers Dis (1999) 1.00
Decrease of frontal metabolism demonstrated by positron emission tomography in a population of healthy elderly volunteers. Acta Neurol Belg (1991) 0.97
Reelin and disabled-1 expression in developing and mature human cortical neurons. J Neuropathol Exp Neurol (2003) 0.97
Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiol Dis (2004) 0.91
Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging (1992) 0.89
Expression profiling in the aging brain: a perspective. Ageing Res Rev (2005) 0.83
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet (2008) 20.38
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
A translational profiling approach for the molecular characterization of CNS cell types. Cell (2008) 8.69
Thinning of the cerebral cortex in aging. Cereb Cortex (2004) 8.31
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function. Proc Natl Acad Sci U S A (2004) 7.70
Identification of genetic variants using bar-coded multiplexed sequencing. Nat Methods (2008) 7.50
Open Access Series of Imaging Studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. J Cogn Neurosci (2007) 7.31
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A (2003) 5.64
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Survival after initial diagnosis of Alzheimer disease. Ann Intern Med (2004) 5.52
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med (2006) 5.28
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord (2007) 5.01
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA (2003) 4.54
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb Cortex (2004) 3.87
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging (2011) 3.83
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry (2009) 3.72
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol (2005) 3.69
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology (2009) 3.56
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement (2011) 3.42
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35